IM Cannabis Secures $225,000 Through Convertible Note Financing Amid Expansion Plans

IM Cannabis Raises $225,000 in Financing

IM Cannabis Corp. (IMCC), a prominent player in the medical cannabis sector, has successfully secured $225,000 through a convertible note financing initiative, underscoring its commitment to expanding its operations in Israel and Germany. The financing deal comes as part of a strategic plan to bolster the company's capital structure, allowing for greater flexibility in its growth strategy.

The recent financing was facilitated through a private placement arrangement with an institutional investor, commonly referred to as the Lender. According to the finalized note purchase agreement dated September 2, 2026, the company issued a convertible note totaling the principal amount of $225,000. Notably, this transaction included an original issuance discount of 10%, which is a favorable term for the investor.

The terms associated with the note offer an interest rate of 8% annually, with an increase to 14% upon the occurrence of any defined event of default. One unique aspect of this financing is that it does not involve cash repayment. Instead, the company's obligations will be settled exclusively through the issuance of its common shares upon conversion of the note.

The conversion price has been set strategically to provide flexibility. It is defined as either a fixed price of $3.328 per Common Share or 90% of the lowest daily volume-weighted average price during the 20 trading days before the conversion date, with a floor price established at $0.665692. Additionally, the company has implemented customary limitations, such as a 4.99% beneficial ownership cap to mitigate any potential dilution of existing shares.

Alongside the issuance of the note, IM Cannabis also granted a warrant, allowing the Lender to purchase up to 77,855 Common Shares at an exercise price of C$4.63 per share. These warrants are effective immediately upon issuance and will remain valid for five years, expiring on September 2, 2031. This aspect of the financing not only incentivizes the Lender but also aligns with the company's future growth prospects.

The net proceeds from this financing initiative will primarily be directed towards general corporate purposes. This strategic allocation is essential for sustaining operations and fostering further growth within the competitive landscape of the medical cannabis industry. Notably, IM Cannabis plans to reserve sufficient common shares for issuance upon conversion of the note and for the exercise of the accompanying warrants.

In line with compliance regulations, the company is also engaged in filing a resale registration statement with the U.S. Securities and Exchange Commission (SEC). This step is crucial as it aims to ensure the proper regulatory framework is followed for the resale of the newly issued securities, thus protecting investor interests while maintaining compliance with securities laws.

Founded with the objective of serving patients in Israel and Germany, IM Cannabis operates through a well-established ecosystem that encompasses importing and distributing cannabis to medical patients. This operational model leverages an impressive database of proprietary insights to inform product offerings and ensure quality control undergoes strict scrutiny throughout the supply chain.

IM Cannabis continues to navigate a highly regulated environment that presents various risks and uncertainties. Challenges such as the potential for unexpected changes in governmental policies, competition, and operational hurdles remain prevalent. However, the company's commitment to maintaining compliance with listing requirements, coupled with strategic growth initiatives, ensures that it remains poised for future success.

For those interested in following IM Cannabis's journey, future updates are expected as the company continues to evolve its positioning in the medical cannabis market. This financing represents a step forward in IM Cannabis's overall strategy to enhance its operational capabilities and address the needs of its patient base in a dynamic industry.

In conclusion, the closing of the $225,000 convertible note financing reflects IM Cannabis's proactive approach to capitalize on growth opportunities, secure essential funding, and fortify its operational framework as it navigates the evolving landscape of the medical cannabis sector.